Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Trial Profile

Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms REASSURE
  • Sponsors Bayer
  • Most Recent Events

    • 10 Feb 2018 Results (n=244)of descriptive analysis safety and baseline characteristics using data from first interim analysis presented at the 2018 Genitourinary Cancers Symposium
    • 19 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Sep 2017 First interim analysis results (n=583) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top